Logo

Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer

Share this

Novartis' Kisqali + Aromatase Inhibitor Receive FDA's Breakthrough Therapy Designation for HR+/HER2- Advanced Breast Cancer

Shots:

  • The FDA’s BT designation is based on P-III MONALEESA-7 study assessing Kisqali + tamoxifen/ aromatase inhibitor + goserelin vs tamoxifen/aromatase inhibitor + goserelin in 672 pre/perimenopausal women with HR+/HER2- advanced breast cancer
  • The P-III MONALEESA-7 study results: mPFS (22.1- 27.5 vs 11.0- 13.8 mos.); AEs: neutropenia (60.6% vs. 3.6%); leukopenia (14.3% vs. 1.2%); no new safety signals observed
  • Kisqali (ribociclib) is a CDK4/6 (cyclin-dependent kinase) inhibitor- approved in the US for postmenopausal women with HR+/HER2- advanced or metastatic breast cancer in combination with aromatase inhibitor and has received its first BT designation based on P-III MONALEESA-2 study in Aug’16.

Ref: Novartis | Image: Value Walk

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions